Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening diseases.
Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting
Data on VT-1161 for the Treatment of RVVC to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever